Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Quetiapine monotherapy in bipolar II depression: Combined data from four large, randomized studies
International Journal of Bipolar Disorders, Volume 1, No. 1, Article 10, Year 2013
Notification
URL copied to clipboard!
Description
Background: Despite being present in up to 1% of the population, few controlled trials have examined the efficacy of treatments for bipolar II depression. Pooled data are presented from four placebo-controlled studies (BOLDER I [5077US/0049] and II [D1447C00135]; EMBOLDEN I [D1447C00001] and II [D1447C00134]) that evaluated the efficacy of quetiapine monotherapy for depressive episodes in patients with bipolar II disorder. Methods: All studies included an 8-week, double-blind treatment phase in which patients were randomly assigned to treatment with quetiapine 300 mg/day, quetiapine 600 mg/day, or placebo. Outcome measures included the change from baseline in MADRS total score at week 8, effect sizes, and MADRS response and remission rates. Results and discussion: Improvements in mean MADRS total scores from baseline to week 8 were significantly greater with quetiapine 300 and 600 mg/day (-15.58 [n = 283] and -14.88 [n = 289]; p < 0.001) compared with placebo (-11.61 [n = 204]). The MADRS effect sizes were 0.44 for quetiapine 300 mg/day and 0.47 for 600 mg/day (p < 0.001 vs placebo). Significantly higher proportions of patients receiving quetiapine, at both doses, than placebo-treated patients achieved response and remission at week 8 (p < 0.01). Common adverse events associated with quetiapine (both doses) included dry mouth, somnolence, sedation, dizziness, and headache. Rates of mania and hypomania were similar for quetiapine and placebo. Quetiapine monotherapy demonstrated significant efficacy compared with placebo and was generally well tolerated in the treatment of bipolar II depression. © 2013 Young et al.
Authors & Co-Authors
Young, Allan H.
United Kingdom, London
Imperial College London
United Kingdom, London
King's College London
Calabrese, Joseph R.
United States, Cleveland
Case Western Reserve University
Gustafsson, Urban
Sweden, Sodertalje
Astrazeneca r and D Södertälje
Berk, Michael
Australia, Geelong
Deakin University
Australia, Melbourne
Orygen Youth Health
Australia, Melbourne
The Florey
Australia, Melbourne
University of Melbourne
McElroy, Susan L.
United States, Mason
Lindner Center of Hope
United States, Cincinnati
University of Cincinnati College of Medicine
Thase, Michael E.
United States, Philadelphia
University of Pennsylvania Perelman School of Medicine
Earley, Willie R.
United Kingdom, Cambridge
Astrazeneca
Statistics
Citations: 25
Authors: 7
Affiliations: 13
Identifiers
Doi:
10.1186/2194-7511-1-10
ISSN:
21947511
Research Areas
Disability
Mental Health
Study Design
Cross Sectional Study